In 2020, the global peripheral vascular device market size was valued at $11.9 billion, with over 16 million yearly peripheral vascular procedures performed. The market size is expected to increase at a compound annual growth rate (CAGR) of 5.2% to reach $16.9 billion in 2026. Throughout this medical market research, we analyzed 113 peripheral vascular

In 2022, the European Peripheral Vascular Devices Market was valued at around €1.5 billion, and it is projected to grow at a CAGR of 3.1% during the forecast period. As a result, it is anticipated to reach approximately €1.9 billion. Throughout this medical device market research, we analyzed over 50 companies within the peripheral vascular

Globally, over 16 million peripheral vascular procedures were performed in 2020. The majority of these procedures were vascular closure device procedures followed by PTA balloon catheter procedures.

The full report suite on the U.S. market for peripheral vascular devices includes peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloon catheters, drug-coated balloons (DCBs), atherectomy devices, intravascular lithotripsy, chronic total occlusion (CTO) devices, surgical grafts, stent grafts, embolic protection devices (EPDs), peripheral thrombus management devices, inferior vena cava filters (IVCFs) and retrieval devices, carotid shunts, transcarotid arterial revascularization (TCAR) flow reversal systems and stents, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths, vascular closure devices (VCDs), transcatheter embolization devices and peripheral IVUS catheters.

Stents are commonly used as complementary devices during conventional percutaneous transluminal angioplasty (PTA) balloon catheterization in peripheral vascular procedures. The placement of a stent mitigates some complications, such as negative remodeling and elastic recoil effects.

The global stent graft market size is expected to reach over $4.8 billion by 2026, while the surgical graft market size is projected to exceed $117 million. Currently, the majority of the global stent market share is controlled by Medtronic and W.L.Gore. AAA stent grafts continued to comprise the largest segment of the stent grafts

This global market research includes 0.014”-0.035” balloons, high-pressure balloons, large balloons greater than 12mm in diameter and specialty balloons. Specialty balloons include cryoplasty balloons, cutting balloons, scoring balloons and other balloons. The analysis also include DCBs used in the superficial femoral artery (SFA) and in AV access procedures.

Thrombosis is defined as the formation of a blood clot inside a blood vessel, which obstructs the flow of blood. Thrombus can become life threatening if it dislodges from the vessel wall and enters the lungs or other vital organ. A fragment of thrombus traveling through the vascular system is called an embolus.

The global peripheral vascular stents market size is expected to reach over $3,828 million by 2026, with the drug-eluting stent market segment showing the highest growth rate.

The majority of the global peripheral vascular stents share was controlled by W.L. Gore, Boston Scientific and Medtronic.

The global peripheral chronic total occlusion (CTO) device market is expected to increase over the forecast period to reach $258.2 million by 2026. This global market research on chronic total occlusion (CTO) devices spans over 70 countries and includes re-canalization and re-entry devices, considered jointly in the analysis.

Atherectomy is a procedure used for removing plaque deposits from arteries. They have traditionally been more effective in peripheral than coronary applications. The success of atherectomies has been driven by the limited performance of existing treatments. Often a blockage is alleviated above the knee, only to have the blood flow deteriorate due to further bottlenecks below the knee. Failure to resolve these vascular limitations can result in critical limb ischemia, ulceration, limb pain or eventual amputation, if left untreated.

Lumen stenosis can occur due to the accumulation of thrombosis or plaque particles in a similar manner to peripheral arterial disease. The accumulation of these plaque particles has also been shown to cause calcification. Lumen stenosis is a considerable problem for both arteriovenous (AV) access surgical grafts and native fistulae because they have poor vessel patency. Due to their tendency to acquire blockages, AV access surgical grafts will require revascularization twice a year, and native fistulae will need to be cleared at least once a year.

Inferior vena cava filters (IVCFs) prevent pulmonary embolism by intercepting a thrombus before it can enter the circulatory system of the lungs. In general, IVCFs are composed of a nest or lattice of wire collapsed around a catheter that is used to guide the filter. The filter is then expanded or deployed at the desired location, usually just below the junction of the inferior vena cava and the lowest renal vein.

Carotid stenting can be accompanied with plaque dislodgment and plaque emboli. Thus, the initial popularity of carotid stents were tainted as these artifacts caused an unacceptably high incidence rate of strokes. Since then, the industry has responded by manufacturing embolic protection devices (EPDs). These devices are used to capture dislodged vascular debris.
There are many different EPD platforms available for use in the peripheral vascular market, including filters, arterial occlusion balloons and devices that redirect blood flow.

Introducer sheaths are used for facilitating the insertion of devices into vasculature. These devices include guidewires and catheters that are used during peripheral interventional procedures. In addition, these devices also simplify the application of patches and closure devices to allow hemostasis to occur.

Chronic total occlusions (CTOs) are complete blockages of arteries. In the case of a hard plaque, over 50% of the occlusion could consist of calcified tissue. Soft plaques typically consist of cholesterol, macrophages and other cells.
The most common method to cross a CTO is to attempt to pass a guidewire through. In other cases, a specialty hydrophilic guidewire may be used. However, if these guidewire-based methods are not sufficient due to poor visualization and calcified heterogeneous lesions, specialized devices must come into play to enable the subsequent deployment of a stent, PTA balloon or even most atherectomy devices.